1. Abatangelo G, Brun P, Cortivo, R (1994) Hyaluronan (Hyaluronic Acid): An Overview. In: Novel Biomaterials Based on Hyaluronic Acid and its Derivatives. Proceedings of a Workshop held at the Annual Meeting of the European Society for Biomaterials. Pisa, S 8-18

2. Agren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E (1999) Proliferation and Mitogenic Response to PDGF-BB of Fibroblasts Isolated from Chronic Venous Leg Ulcers is Ulcer-Age Dependent. J. Invest. Dermatol. 112: 463-469

3. Ambrosch A, Lehnert H, Lobmann R (2003) Mikrobiologische Aspekte und rationelle antibiotische Therapie des diabetischen Fußsyndroms. Med Klein 98: 259-265

4. Anonymus (2002) Materialkunde Teil I: Calciumalginate – Verbandstoff aus dem Meer. HARTMANN WundForum 3/2002: 25-29

5. Anonymus (2003) Chronisch-stagnierende Wunden: Aus der Flaute - volle Fahrt in Richtung Heilungserfolg. Zeitschrift für Wundheilung 8: 148-152

6. Armstrong DG, Boulton AJM, Banwell P (2004) Negative Pressure Wound Therapy in Treatment of Diabetic Foot Wounds: A Marriage of Modalities. OWM 50 (4A-Suppl), Proc. 2003 National V.A.C. Education Conf.: 9-12

7. Armstrong DG, Lavery LA, Abu-Rumman P, Espensen EH, Vazquez JR, Nixon BP, Boulton AJM (2002) Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot. OWM 48: 64-68

8. Asmussen PD, Söllner B (1993) Wundversorgung. Band 1: Prinzipien der Wundheilung. Hippokrates Verlag Stuttgart

9. Benedetti L, Bellini D, Renier D, O'Regan M (1994) Chemical Modification of Hyaluronan. In: Novel Biomaterials Based on Hyaluronic Acid and its Derivatives. Proceedings of a Workshop held at the Annual Meeting of the European Society for Biomaterials. Pisa, S 20-29

10. Bonn D (2000) Maggot therapy: an alternative for wound infection. Lancet 356: 1174

11. Bowler PG (2003) The 10(5) bacterial growth guideline: reassessing its clinical relevance in wound healing. Ostomy/Wound Management 49: 44-53

12. Bradley M, Cullum N, Sheldon T (1999) The debridement of chronic wounds: a systematic review. Health Technology Assessment, 3, No. 17 (PT I)

13. Bradshaw T, Gem J, Boulton, A (1989) The Use of Kaltostat in the Treatment of Ulceration in the Diabetic Foot. Chiropodist Sep.: 204-207

14. Brandt H, Kammerlander G, Eberlein, T, Huhn A. (2003) Wundversorgung. In: Manuale zur Pharmazeutischen Betreuung Bd 5, Govi-Verlag, Eschborn

15. Braun M (1997) Dekubitusbehandlung und Therapie von Grunderkrankungen. In: Bienstein C, Schröder G, Braun M, Neander K-D (Hrsg.) Dekubitus. Georg Thieme Verlag, Stuttgart, New York: 149-155

16. Briggs M, Torra i Bou JE (2002) Schmerzen beim Wundverbandwechsel: ein Behandlungsleitfaden. Positions-Dokument EWMA, Medical Education Partnership Ltd., London, S 12-17

17. Briggs M, Nelson, EA (2004) Topical agents or dressings for pain in venous leg ulcers (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd.

18. Cantor A (2002) Hyaluronan as a Treatment for Chronic Recalcitrant Wounds. In: The Oxford European Wound Healing Course Handbook. Positif Press, Oxford, S 136-144

19. Carson SN, Overall K, Lee-Jahshan S, Travis E (2004) Vacuum-Assisted Closure Used für Healing Chronic Wounds and Skin Grafts in the Lower Extremities. OWM 50: 52-58

20. Chen WYJ, Abatangelo G (1999) Functions of hyaluronan in wound repair. Wound Rep Reg 7: 79-89

21. Christophers E, Ständer M (2003) Urban & Fischer Verlag München, Jena

22. Cochrane ChA, Walker M, Bowler PG (2004) Effect of a silver-containing Hydrofiber dressing on matrix metalloproteinase and elastase activity. 17th Annual Symposium on Advanced Wound Care & 14th Medical Research Forum on Wound Repair. Abstract Review. OWM 50: 85

23. Campoccia D, Hunt JA, Doherty PJ, Zhong SP, Oregan M, Benedetti L, Williams DF (1996) Quantitative assessment of the tissue response to films of hyaluronan derivatives. Biomaterials 17: 963-975

24. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L (2002a) Mechanism of action of Promogran, a protease modulating matrix, for the treatment if diabetic foot ulcers. Wound Rep Reg 10: 16-25

25. Cullen B, Watt PW, Lundqvist Ch, Silcock D, Schmidt RJ, Bogan D, Light ND (2002b) The role of oxidised regenerated cellulose/collagen in chronic wound repair and ist potential mechanism of action. International J Biochem Cell Biology 34: 1544-1556

26. Deutschmann G (2005) Die Haut und ihre Anhangsgebilde. Springer Wien New York

27. Dolynchuk KN (2001) Debridement. In: Krasner DL, Rodeheaver, GT, Sibbald, RG (Hrsg) Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Third Edition, HMP Communications, Wayne, S 385-390

28. Dissemond J (2004) Der Einfluss des pH-Wertes auf die Wundheilung. Zeitschrift für Wundheilung Nr. 5/2004: 242-243

29. Edwards R, Harding KG (2004) Bacteria and wound healing. Curr Opin Infect Dis. 17: 91-96

30. Elias PM, Grayson S, Lampe MA, Williams ML, Brown BE (1983) The intercorneocyte space. In: Marks R, Plewig G (eds.): Stratum corneum. Springer Verlag, Berlin Heidelberg New York, S. 53-67

31. Expertenstandard Dekubitus

32. Fernandez R, Griffiths R, Ussia C (2004) Water for wound cleansing (Cochrane Review). The Cochrane Library, Issue 2, Chichester, UK: John Wiley & Sons, Ltd.

33. Fleischmann W, Grassberger M (2002) Maden-Therapie. TRIAS Verlag, Stuttgart

34. Fleischmann W, Russ M, Moch, D, Marquardt Ch (1999) Biochirurgie – Sind Fliegenmaden wirklich die besseren Chirurgen? Chirurg 70: 1340-1346

35. Fleischmann W, Russ M, Westhauser A, Stampehl M (1998) Die Vakuumversiegelung als Trägersystem für eine gezielte lokale Medikamentenapplikation bei Wundinfektionen. Unfallchirurg 101: 649-654

36. Foster AM, Bates M, Doxford M, Edmonds ME (1999) The Treatment of Indolent Neuropathic Ulceration of the Diabetic Foot with Hyaff an ester of Hyaluronic Acid. EASD, 35th Annual Meeting, Brüssel, Abstract 105, A 29

37. Garrett B, Cert AE, Garrett SB (1997) Cellular communication and the action of growth factors during wound healing. Journal of Wound Care 6: 277-280

38. Gauger A, Mempel M, Schekatz A, Schäfer T (2003): Silver-Coated Textiles Reduce Staphylococcus aureus Colonization in Patients with Atopic Eczema. Dermatology 207: 15-21

39. Glover JL, Weingarten MS, Buchbinder DS, Poucher, RL, Deitrick GA, Fylling CP (1997) A 4-Year Outcome-Based Retrospective Study of Wound Healing and Limb Salvage in Patients with Chronic Wounds. Adv Wound Care 10: 33-38

40. Gottrup F (2002) Wound Debridement. In: The Oxford European Wound Healing Course Handbook. Positif Press, Oxford, S 116-120

41. Gregory S-J, Cullen B (2002) A comparison of Promogran (Orc/Collagen) and other biopolymers to modify the chronic wound environment. Zeitschrift für Wundheilung 7: 116-117, Posterabstract 11

42. Hehenberger K, Kratz G, Hansson A, Brismar K (1998) Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. Journal of Dermatological Science 16: 144-151

43. Hipler UC, Elsner P, Fluhr JW (2005) Antifungal and antibacterial properties of a silver-loaded cellulosic fiber. J Biomed Mater Res B Appl Biomater. 2005 Oct 21

44. Hughes MA (2002) The Science of Wound Healing. In: The Oxford European Wound Healing Course Handbook. Positif Press, Oxford, S 11-19

45. Kammerlander G (1998) Lokaltherapeutische Standards für chronische Hautwunden. Springer-Verlag Wien

46. Konsensus der Deutschen und der Österreichischen Gesellschaften für Wundheilung und Wundbehandlung zur Vakuumversiegelung und "V.A.C.-Therapie Einheit" (2003) ZfW 8: 242-246

47. Konsensusempfehlung Wundantiseptik (2004) Konsensusempfehlung zur Auswahl von Wirkstoffen für die Wundantiseptik. ZfW 9: 110-120

48. Kraft JN, Lynde CW (2005) Moisturizers: What They Are and a Practical Approach to Product Selection. Skin Therapy Lett. 10 (5): 1-8

49. Laing P (1994) Diabetic Foot Ulcers. American Journal of surgery 167 (Suppl 1A): 31S –36S

50. LBK Hamburg (2003) Wundfibel. Consulting in der Gesundheitswirtschaft, Hamburg

51. Leitlinie Dekubitus ICW

52. Li VW, Li WW (2003b) Angiogenic Therapy for Chronic Wounds: The Clinical Experience with Beclapermin. Contemporary Surgery, Suppl. Nov. 2003: 26 -32

53. Li WW, Li VW (2003a) Therapeutic Angiogenesis: Using Growth Factors to Restore Circulation in Damaged Tissues. Contemporary Surgery, Suppl. Nov. 2003: 19 – 25

54. Lobmann R (1999) Konservative Therapie des diabetischen Fußes aus internistischer Sicht. Diabetes und Stoffwechsel 8 (Suppl 5): 9-11

55. Lobmann R, Schladitz A, Lehnert H (2004) Die Hauttrophik von Diabetikern und stoffwechselgesunden Kontrollen unterscheiden sich und die Behandlung mit einer harnstoffhaltigen Salbe führt zu einer Verbesserung. Diabetes und Stoffwechsel, Suppl. 1, 13: 84

56. Lobmann R, Schultz G, Lehnert H (2003) Molekulare Grundlagen der Wundheilung bei diabetischem Fußsyndrom. Med Klin 98: 292-301

57. Loden M (2003) Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders. Am J Clin Dermatol 4 (11): 771-788

58. Lorée S, Dompmartin A., Penven K, Harel D, Leroy D (2004) Is Vacuum Assisted Closure a valid technique for debreding chronic leg ulcers?. Journal of Wound Care 13: 249-252

59. Mannari R, Payne WG, Ochs DE, Walusimbi M, Blue M, Robson M (2002) Successful Treatment of Recalcitrant, Diabetic Heel ulcers with Topical Becaplermin (rhPDGF-BB) Gel. Wounds 14: 116-121

60. Marino Ch (2001) Skin Physiology, Irritants, Dry Skin and Moisturizers. Washington State Department of Labor and Industries, Rep. No. 56-2-2001

61. Marks R (2004) The Stratum Corneum Barrier: The Final Frontier. J. Nutr. 134: 2017S-2021S

62. Mast BA, Shultz GS (1996) Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Rep Reg 4: 411-420

63. Meuleneire F (2001) TenderWet bei der Reinigung von Wunden – Praxisbeobachtungen. HARTMANN WundForum 1/2001: 21-25

64. Moch D, Fleischmann W, Russ M (1999) Das BMW-Konzept beim diabetischen Fuß. Zentralbl Chir. 124 Suppl 1: 69-72

65. Morbach St, Hoffmeier H, Ochs H-R (2002) An in-use observational study of the treatment of diabetic foot ulcers with protease modulating matrix and Becaplermin gel. In: 17th Annual Clinical Symposium on Advances in Skin & Woundcare, September 21-24, 2002, Dallas, Texas, Poster 50

66. Müller G, Winkler Y, Kramer A (2003) Antibacterial activity and endotoxin-binding capacity of Actisorb Silver 220. Journal of Hospital Infection 53: 211-214

67. National Pressure Ulcer Advisory Panel 1998

68. Neander K-D (2004) Dekubitusprophylaxe. Der Expertenstandard und die Praxis. Vincentz Network

69. Niedner R (1995) Inhibition of Wound Healing by Topical Anti-microbial Agents. In: Altmeyer P, Hoffmann K, el Gammal S, Hutchinson J (1995) Wound Healing and Skin Physiology. Springer-Verlag: S 435-448

70. Piaggesi A, Baccetti F, Rizzo L, Romanelli M, Navalesi R, Benzi L (2001) Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot. Diabet Med 18: 320-324

71. Piaggesi A, Schipani E, Campi F, Romanelli M, Baccetti F, Arvia C, Navalesi R (1998) Conservative Surgical Approach versus Non-Surgical Management for Diabetic Neuropathic Foot Ulcers: a Randomized Trial. Diabet. Med. 15: 412-417

72. Probst W, Vasel-Biergans A (2004) Wundmanagement. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

73. Reike H (1999) Infektionen beim diabetischen Fuß-Syndrom. In: Reike H (Hrsg) Diabetisches Fuß-Syndrom. Walter de Gruyter, Berlin, New York: S 95-119

74. Scharffetter-Kochanek K, Schüller J, Meewes Ch, Hinrichs R, Eich D, Eming S, Wenk J, Wlaschek M (2003) Das chronisch venöse Ulcus cruris. Pathogenese und Bedeutung des "aggressiven Mikromilieus". Journal der Dt. Dermatologiaschen Gesellschaft 1: 58-68

75. Schöbel K. (1995) Liposomen, Gerbstoffe und essentielle Fettsäuren für die Pflege und Regeneration der Haut. Verlag Dr. Kovac Hamburg

76. Schultz GS, Sibbald RG, Falanga V, Ayello E, Dowsett C, Harding K, Romanelli M, Stacey MC, Teot L, Vanscheidt W (2003) Wound bed preparation: a systematic approach to wound management. Wound Rep Reg 11: 1-28

77. Schürer N, Kresken J (2000) Die trockene Haut. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

78. Schwarzkopf A (2002) Die Mikrobiologie der Wunde. ZfW 7: 214-216

79. Schwarzkopf A (2003) Betrachtungen zur Hygiene bei der Wundversorgung. ZfW 8: 82-84

80. Seiler WO, Stähelin HB (1993) Dekubitus. In: Sedlarik KM (Hrsg) Wundheilung. Gustav Fischer Verlag, Jena, Stuttgart: S 192-212

81. Seipp HM, Hofmann S, Hack A, Skowronsky A, Hauri A (2005) Wirksamkeit verschiedener Wundspüllösungen gegenüber Biofilmen. Zeitschrift für Wundheilung Nr. 4/2005: 160-164

82. Sherman RA (2003) Maggot therapy for Treating Diabetic Foot Ulcers Unresponsive to Conventional Therapy. Diabetes Care 26: 446-451

83. Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D (2003) Preparing the Wound Bed 2003: Focus on Infection and Inflammation. Ostomy/Wound Management 49: 24-51

84. Siebenschuh I, Rösken F, Koschnik M, Menger MD, Mutschler W (1998) Hyaluronsäure in der Wundbehandlung. Zeitschrift für Wundbehandlung 3: 6-8

85. Silhi N (1998) Diabetes and wound healing. Journal of Wound Care 7: 47-51

86. Singer, AJ, Clark RAF (1999) Mechanisms of Disease. Cutaneous Wound Healing. The New England Journal of Medicine 341: 738-746

87. Skin Care Forum (2003) Nr.35. www.scf-online.com/german/35_d/frontpage35_d.htm (07.10.2005)

88. Smiell JM, Wieman J, Steed DL, Perry BH, Sampson AR, Schwab BH (1999) Efficacy and safety of becaplermin (recombinant human platetelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regeneration 7: 335-346

89. Smith J (2003) Debridement of diabetic foot ulcers. The Cochrane Library, Issue 1, CD 003556, Update Software: 22 Seiten

90. Stadler R, Wallenfang K (2002) Anwendungsbeobachtung der aktivkohlehaltigen Wundauflage Actisorb bei 12444 Patienten mit chronischen Wunden. Akt Dermatol 28: 351-354

91. Steed DL, Donohoe D, Webster MW, Lindsley L (1996) Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J. Am. Coll. Surg. 183: 61-64

92. Tanczos E, Horch RE, Bannasch H, Andree C, Walgenbach K-J, Voigt M, Stark GB (1999) Keratinozytentransplantation und Tissue Engineering. Zentralbl Chir. 124, Suppl 1: 81-86

93. Tausche AK, Skaria M, Böhlen L, Liebold K, Hafner J, Friedlein H, Meurer M, Goedkopp RJ, Wollina U, Salomon D, Hunziker T (2003) An autologous epidermal equivalent tissue-engineered from follicular outer sheath keratinocytes is a effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Rep Reg 11: 248-252

94. Tautenhahn J, Bürger T, Lippert H (2004) Der Stand der Vakuumversiegelung. Der Chirurg 75: 492-497

95. Thomas S (1990) Wound Management and Dressings. The Pharmaceutical Press London

96. Thomas S, Andrews A, Hay N, Bourgoise S (1999) The anti-microbial activity of maggot secretions: results of a preliminary study. Journal of Tissue Viability 9: 127-132

97. Thomas S, McCubbin P (2003) A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. Journal of Wound Care 12: 101-107

98. Vazquez JR, Short B, Findlow AH, Nixon BP, Boulton AJ, Armstrong DG (2003) Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract. 59: 123-127

99. Veves A, Sheehan P, Pham HT (2002) A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch. Surg. 137: 822-827

100. Wallenfang K, Westenberger-Treumann M, Stadler R (2001) Wundheilungskonzept mit heute zur Verfügung stehenden Wundverbänden zur phasenadaptierten Wundbehandlung. Akt Dermatol 27: 343-350

101. Weigel PH, Frost SJ, McGarty CT, Leboeuf RD (1988) The role of hyaluronic acid in inflammation and wound healing. Int. J. Tiss. Reac. X 6: 355 - 365

102. Williams C (1999) An investigation of the benefits of Aquacel Hydrofibre wound dressing. Br J Nurs. 1999 8: 676-7, 680

103. Winter GD, Scales JT (1963) Effekt of Air Drying and Dressings on the Surface of the Wound. Nature, 197: 91-92

104. Wohlrab W (1988) Welche Harnstoffkonzentration ist für die externe Therapie notwendig? Dermatol. Mon.schr. 174: 94-98

105. Wohlrab WA (1993) Harnstoff in der externen Therapie von Hauterkrankungen – Grundlagen und Anwendung. Z. ärztl. Fortbild. 87: 643-650

106. Wolff H, Hansson C (2003) Larval therapy – an effective method of ulcer debridement. Clinical and Experimental Dermatology 28: 134-137

107. Wright JB, Lam K, Burrell RE (1998) Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Am J Infect Control 26: 572-577

108. Wright JB, Lam K, Hansen D, Burrell RE (1999) Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 27: 344-350

109. Young MJ (1993) The Use of Alginates in the Management of Exudating, Infected Wounds: Case Studies. DERMATOLOGY NURSING 5: 359-363, 356

110. Zegelin A (1997) Skalen zur Ermittlung des Dekubitusrisikos. In: Bienstein C, Schröder G, Braun M, Neander K-D (Hrsg.) Dekubitus. Georg Thieme Verlag, Stuttgart, New York: 91-93

111. Ziegler UE, Debus ES, Keller HP, Thiede A (2001) Hautersatzverfahren bei chronischen Wunden. Zentralblatt Chirurgie 126, Suppl. 1: 71-74